• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

在激素受体阳性、人表皮生长因子受体2阴性、无淋巴结转移的浸润性乳腺癌中,Ki-67标记指数采用3种不同临界值、组织学分级和核分级的预后影响。

Prognostic impact of Ki-67 labeling indices with 3 different cutoff values, histological grade, and nuclear grade in hormone-receptor-positive, HER2-negative, node-negative invasive breast cancers.

作者信息

Ono Makiko, Tsuda Hitoshi, Yunokawa Mayu, Yonemori Kan, Shimizu Chikako, Tamura Kenji, Kinoshita Takayuki, Fujiwara Yasuhiro

机构信息

Division of Molecular and Cellular Medicine, National Cancer Center Research Institute, Tokyo, Japan,

出版信息

Breast Cancer. 2015 Mar;22(2):141-52. doi: 10.1007/s12282-013-0464-4. Epub 2013 Apr 13.

DOI:10.1007/s12282-013-0464-4
PMID:23584595
Abstract

BACKGROUND

The criteria for classifying hormone receptor (HR)-positive/HER2-negative breast cancers into low-risk and high-risk subgroups remain undetermined. Supportive data for optimal criteria to identify tumors in the high-risk subgroup are necessary for Japanese patients with HR-positive/HER2-negative breast cancers.

METHODS

Using immunohistochemistry and fluorescence in situ hybridization, we identified 369 consecutive patients with HR-positive/HER2-negative, node-negative invasive breast cancers. We examined the prognostic impact of the Ki-67 labeling index (LI) based on 3 cutoff values, 10, 14, and 20 %, along with that of histological grade (HG) and nuclear grade (NG) by Cox's univariate and multivariate analyses.

RESULTS

The univariate analyses clearly showed that Ki-67 LI with any cutoff value divided the patients into distinct high-risk and low-risk groups, and that HG and NG were also powerful prognostic indicators. High Ki-67 LI with any cutoff value was strongly correlated with HG and NG, and when these parameters were included in the multivariate analyses, the impact of HG/NG was stronger than Ki-67 LIs. When the 10 % cutoff value was adopted, discordance between Ki-67 LI and grades was frequent in papillotubular-type invasive ductal carcinoma, predominantly intraductal carcinoma, and mucinous carcinoma.

CONCLUSIONS

Any of the Ki-67 LI values, regardless of cutoff value, could be applicable for the classification of high-risk and low-risk HR-positive/HER2-negative, node-negative invasive breast cancers. Luminal A/B subtyping according to Ki-67 LI, or HG/NG, in combination with histological type, appeared to be able to create an optimum risk estimation system for patients with HR-positive/HER2-negative, node-negative invasive breast cancers in Japan.

摘要

背景

激素受体(HR)阳性/人表皮生长因子受体2(HER2)阴性乳腺癌分为低风险和高风险亚组的标准尚未确定。对于日本HR阳性/HER2阴性乳腺癌患者而言,确定用于识别高风险亚组肿瘤的最佳标准的支持性数据很有必要。

方法

我们使用免疫组织化学和荧光原位杂交技术,确定了369例连续的HR阳性/HER2阴性、无淋巴结转移的浸润性乳腺癌患者。我们通过Cox单因素和多因素分析,研究了基于10%、14%和20%这三个临界值的Ki-67标记指数(LI)以及组织学分级(HG)和核分级(NG)的预后影响。

结果

单因素分析清楚地表明,任何临界值的Ki-67 LI都能将患者分为明显的高风险和低风险组,并且HG和NG也是强大的预后指标。任何临界值的高Ki-67 LI都与HG和NG密切相关,当这些参数纳入多因素分析时,HG/NG的影响比Ki-67 LI更强。当采用10%的临界值时,在乳头管状型浸润性导管癌、主要为导管内癌和黏液癌中,Ki-67 LI与分级之间的不一致很常见。

结论

无论临界值如何,任何Ki-67 LI值都可用于HR阳性/HER2阴性、无淋巴结转移的浸润性乳腺癌的高风险和低风险分类。根据Ki-67 LI或HG/NG,并结合组织学类型进行管腔A/B亚型分类,似乎能够为日本HR阳性/HER2阴性、无淋巴结转移的浸润性乳腺癌患者建立一个最佳的风险评估系统。

相似文献

1
Prognostic impact of Ki-67 labeling indices with 3 different cutoff values, histological grade, and nuclear grade in hormone-receptor-positive, HER2-negative, node-negative invasive breast cancers.在激素受体阳性、人表皮生长因子受体2阴性、无淋巴结转移的浸润性乳腺癌中,Ki-67标记指数采用3种不同临界值、组织学分级和核分级的预后影响。
Breast Cancer. 2015 Mar;22(2):141-52. doi: 10.1007/s12282-013-0464-4. Epub 2013 Apr 13.
2
Analysis of clinically relevant values of Ki-67 labeling index in Japanese breast cancer patients.日本乳腺癌患者中Ki-67标记指数的临床相关值分析。
Breast Cancer. 2014 May;21(3):325-33. doi: 10.1007/s12282-012-0387-5. Epub 2012 Jul 11.
3
Prognostic Significance of Progesterone Receptor Expression in Estrogen-Receptor Positive, HER2-Negative, Node-Negative Invasive Breast Cancer With a Low Ki-67 Labeling Index.孕激素受体表达在雌激素受体阳性、人表皮生长因子受体2阴性、淋巴结阴性且Ki-67标记指数低的浸润性乳腺癌中的预后意义
Clin Breast Cancer. 2017 Feb;17(1):41-47. doi: 10.1016/j.clbc.2016.06.012. Epub 2016 Jun 25.
4
Topoisomerase II alpha expression and the Ki-67 labeling index correlate with prognostic factors in estrogen receptor-positive and human epidermal growth factor type-2-negative breast cancer.拓扑异构酶 II alpha 表达和 Ki-67 标记指数与雌激素受体阳性和人表皮生长因子受体 2 阴性乳腺癌的预后因素相关。
Breast Cancer. 2012 Oct;19(4):309-14. doi: 10.1007/s12282-011-0291-4. Epub 2011 Jul 2.
5
Prognostic value of proliferation assay in the luminal, HER2-positive, and triple-negative biologic classes of breast cancer.在乳腺癌的腔面型、HER2 阳性和三阴性生物学分类中,增殖测定的预后价值。
Breast Cancer Res. 2012 Jan 6;14(1):R3. doi: 10.1186/bcr3084.
6
Power of PgR expression as a prognostic factor for ER-positive/HER2-negative breast cancer patients at intermediate risk classified by the Ki67 labeling index.PgR表达作为通过Ki67标记指数分类的中度风险ER阳性/HER2阴性乳腺癌患者预后因素的作用。
BMC Cancer. 2017 May 22;17(1):354. doi: 10.1186/s12885-017-3331-4.
7
Ki-67 is a prognostic marker for hormone receptor positive tumors.Ki-67是激素受体阳性肿瘤的一个预后标志物。
Clin Transl Oncol. 2016 Oct;18(10):996-1002. doi: 10.1007/s12094-015-1472-y. Epub 2016 Jan 7.
8
Identification of Luminal Subtypes of Breast Carcinoma Using Surrogate Immunohistochemical Markers and Ascertaining Their Prognostic Relevance.使用替代免疫组织化学标志物鉴定乳腺癌的腔型亚型并确定其预后相关性。
Clin Breast Cancer. 2020 Oct;20(5):382-389. doi: 10.1016/j.clbc.2020.03.012. Epub 2020 Apr 6.
9
Discordance of hormone receptor, human epidermal growth factor receptor-2, and Ki-67 between primary breast cancer and synchronous axillary lymph node metastasis.原发性乳腺癌与同步腋窝淋巴结转移之间激素受体、人表皮生长因子受体-2和Ki-67的不一致性。
J BUON. 2018 Dec;23(7):60-66.
10
Prognostic values of negative estrogen or progesterone receptor expression in patients with luminal B HER2-negative breast cancer.雌激素或孕激素受体阴性表达在腔面B型HER2阴性乳腺癌患者中的预后价值
World J Surg Oncol. 2016 Sep 13;14(1):244. doi: 10.1186/s12957-016-0999-x.

引用本文的文献

1
Assessment of nuclear grade-based recurrence risk classification in patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative, node-positive high-risk early breast cancer.基于核分级的激素受体阳性、人表皮生长因子受体 2 阴性、淋巴结阳性高危早期乳腺癌患者复发风险分类评估。
Breast Cancer. 2023 Nov;30(6):1054-1064. doi: 10.1007/s12282-023-01500-2. Epub 2023 Aug 23.
2
The Evolution of Ki-67 and Breast Carcinoma: Past Observations, Present Directions, and Future Considerations.Ki-67与乳腺癌的演变:过去的观察、当前的方向及未来的考量
Cancers (Basel). 2023 Jan 28;15(3):808. doi: 10.3390/cancers15030808.
3
Validation of a nuclear grading system for resected stage I-IIIA, high-risk, node-negative invasive breast carcinoma in the N·SAS-BC 01 trial.
在N·SAS-BC 01试验中对I-IIIA期、高危、淋巴结阴性浸润性乳腺癌切除标本的核分级系统进行验证。
Breast Cancer. 2022 Jul;29(4):720-729. doi: 10.1007/s12282-022-01350-4. Epub 2022 Apr 18.
4
Preoperative Nomogram for Predicting Sentinel Lymph Node Metastasis Risk in Breast Cancer: A Potential Application on Omitting Sentinel Lymph Node Biopsy.预测乳腺癌前哨淋巴结转移风险的术前列线图:在省略前哨淋巴结活检中的潜在应用
Front Oncol. 2021 Apr 26;11:665240. doi: 10.3389/fonc.2021.665240. eCollection 2021.
5
Comparison between AJCC 8th prognostic stage and UICC anatomical stage in patients with primary breast cancer: a single institutional retrospective study.AJCC 第 8 版预后分期与 UICC 解剖分期在原发性乳腺癌患者中的比较:单机构回顾性研究。
Breast Cancer. 2020 Nov;27(6):1114-1125. doi: 10.1007/s12282-020-01115-x. Epub 2020 Jun 3.
6
Do YOU know the Ki-67 index of your breast cancer patients? Knowledge of your institution's Ki-67 index distribution and its robustness is essential for decision-making in early breast cancer.您了解您的乳腺癌患者的 Ki-67 指数吗?了解您所在机构的 Ki-67 指数分布及其稳健性对于早期乳腺癌的决策至关重要。
Breast. 2020 Jun;51:120-126. doi: 10.1016/j.breast.2020.03.005. Epub 2020 Mar 23.
7
Androgen receptor and FOXA1 coexpression define a "luminal-AR" subtype of feline mammary carcinomas, spontaneous models of breast cancer.雄激素受体和 FOXA1 的共表达定义了一种“腔面雄激素受体”的猫乳腺肿瘤亚型,这是乳腺癌的自发模型。
BMC Cancer. 2019 Dec 30;19(1):1267. doi: 10.1186/s12885-019-6483-6.
8
Proposal for a Histological Staging System of Mammary Carcinomas in Dogs and Cats. Part 1: Canine Mammary Carcinomas.犬猫乳腺癌组织学分期系统的建议。第1部分:犬乳腺癌
Front Vet Sci. 2019 Nov 7;6:388. doi: 10.3389/fvets.2019.00388. eCollection 2019.
9
Gene Alterations in Triple-Negative Breast Cancer Patients in a Phase I/II Study of Eribulin and Olaparib Combination Therapy.在一项关于艾瑞布林和奥拉帕尼联合治疗的I/II期研究中三阴性乳腺癌患者的基因改变
Transl Oncol. 2019 Oct;12(10):1386-1394. doi: 10.1016/j.tranon.2019.07.013. Epub 2019 Aug 2.
10
Array comparative genomic hybridization analysis discloses chromosome copy number alterations as indicators of patient outcome in lymph node-negative breast cancer.阵列比较基因组杂交分析揭示染色体拷贝数改变可作为淋巴结阴性乳腺癌患者预后的指标。
BMC Cancer. 2019 May 30;19(1):521. doi: 10.1186/s12885-019-5737-7.